Table 5.
Analyses of Prognostic Factors for Overall Survival
| Factor | Univariable Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Regorafenib alone | 1.690 (1.069–2.670) | 0.025 | 1.630 (1.031–2.578) | 0.037 |
| Female | 1.284 (0.658–2.505) | 0.463 | ||
| >65 years | 0.746 (0.338–1.647) | 0.468 | ||
| ECOG score = 1 | 1.592 (1.009–2.514) | 0.046 | 0.160 | |
| Positive for HbsAg | 0.631 (0.303–1.317) | 0.220 | ||
| Child-Pugh B | 1.661 (1.044–2.642) | 0.032 | 1.595 (1.002–2.540) | 0.049 |
| Presence of ascites | 0.968 (0.574–1.632) | 0.902 | ||
| Tumor diameter (per cm) | 1.034 (0.972–1.100) | 0.288 | ||
| Tumor >5 cm | 1.215 (0.747–1.974) | 0.433 | ||
| >3 intrahepatic tumors | 1.703 (0.978–2.965) | 0.060 | 0.257 | |
| Macrovascular invasion | 1.149 (0.713–1.850) | 0.569 | ||
| Extrahepatic metastasis | 1.326 (0.819–2.147) | 0.251 | ||
| First-line treatment with lenvatinib | 0.883 (0.555–1.405) | 0.600 | ||
| Time on first-line treatment (per month) | 0.996 (0.981–1.012) | 0.626 | ||
| Previous surgery or ablation | 0.713 (0.404–1.257) | 0.243 | ||
| α-fetoprotein (per 104 ng/mL) | 1.020 (1.000–1.040) | 0.045 | 0.223 | |
| Alanine aminotransferase >50 U/L | 1.520 (0.917–2.519) | 0.105 | ||
| Aspartate aminotransferase >40 U/L | 2.039 (1.262–3.295) | 0.004 | 0.116 | |
| Total bilirubin >22 μmol/L | 1.555 (0.941–2.571) | 0.085 | 0.243 | |
| Albumin <35 g/dL | 1.371 (0.869–2.161) | 0.175 | ||
| Lymphocyte <1.16*109/L | 1.975 (1.168–3.341) | 0.011 | 0.165 | |
| Neutrophils >3.16*109/L | 2.278 (1.442–3.599) | < 0.001 | 0.066 | |
| Platelet of 100–200*109/L | Ref | |||
| Platelet <100*109/L | 1.226 (0.700–2.147) | 0.477 | 0.682 | |
| Platelet >200*109/L | 1.321 (0.723–2.413) | 0.365 | 0.624 | |
| NLR >3.6 | 2.610 (1.641–4.150) | < 0.001 | 1.897 (1.075–3.348) | 0.027 |
| PLR >190 | 2.360 (1.476–3.773) | < 0.001 | 0.133 | |
| Study Center 1 a | Ref | |||
| Study Center 2 b | 0.684 (0.375–1.246) | 0.214 | ||
| Study Center 3 c | 1.141 (0.636–2.048) | 0.659 | ||
Notes: The uni- and multi-variate analyses were performed using Cox proportional hazard regression model. aThe Second Affiliated Hospital of Guangzhou Medical University. bJieyang People’s Hospital. cThe First People’s Hospital of Zhaoqing.
Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HBsAg, hepatitis B surface antigen; PIVKA-II, protein induced by vitamin K absence or antagonist-II; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.